- Home
- DSM vs AVIR Comparison
DSM vs AVIR Comparison
Compare DSM & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSM
- AVIR
- Stock Information
- Founded
- DSM 1989
- AVIR 2012
- Country
- DSM United States
- AVIR United States
- Employees
- DSM N/A
- AVIR N/A
- Industry
- DSM Investment Managers
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- DSM Finance
- AVIR Health Care
- Exchange
- DSM Nasdaq
- AVIR Nasdaq
- Market Cap
- DSM 301.0M
- AVIR 247.5M
- IPO Year
- DSM N/A
- AVIR 2020
- Fundamental
- Price
- DSM $5.76
- AVIR $3.25
- Analyst Decision
- DSM
- AVIR Hold
- Analyst Count
- DSM 0
- AVIR 1
- Target Price
- DSM N/A
- AVIR $6.88
- AVG Volume (30 Days)
- DSM 161.7K
- AVIR 503.8K
- Earning Date
- DSM 01-01-0001
- AVIR 11-07-2024
- Dividend Yield
- DSM 3.97%
- AVIR N/A
- EPS Growth
- DSM N/A
- AVIR N/A
- EPS
- DSM N/A
- AVIR N/A
- Revenue
- DSM N/A
- AVIR N/A
- Revenue This Year
- DSM N/A
- AVIR N/A
- Revenue Next Year
- DSM N/A
- AVIR N/A
- P/E Ratio
- DSM N/A
- AVIR N/A
- Revenue Growth
- DSM N/A
- AVIR N/A
- 52 Week Low
- DSM $4.69
- AVIR $2.75
- 52 Week High
- DSM $6.05
- AVIR $4.60
- Technical
- Relative Strength Index (RSI)
- DSM 24.12
- AVIR 53.11
- Support Level
- DSM $5.76
- AVIR $3.10
- Resistance Level
- DSM $6.18
- AVIR $3.32
- Average True Range (ATR)
- DSM 0.05
- AVIR 0.14
- MACD
- DSM -0.04
- AVIR 0.03
- Stochastic Oscillator
- DSM 0.00
- AVIR 87.61
About DSM BNY Mellon Strategic Municipal Bond Fund Inc.
BNY Mellon Strategic Municipal Bond Fund, Inc. is a diversified closed-end management investment company. Its investment objective is to seek to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).